Novartis Consumer Health Canada, Inc. advises the public of its issuance of a voluntary recall of 17 cough and cold products due to a defect on the child-resistant mechanism of the bottle caps. This poses a health risk to children as they may be able to open these bottles and ingest the product, which may cause serious adverse health consequences, including death. Information on the 17 cough and cold products recalled is provided at www.hc-sc.gc.ca/ahc-asc/ media/advisories-avis/_2013/2013_16-eng.php. Advise patients to contact Novartis Consumer Canada, Inc. at 1-866-513-6742 for further information on this recall.
Health Canada alerts the public that it is conducting an ongoing safety review of Diane-35 (cyproterone acetate 2 mg with ethinyl estradiol 35 mcg by Bayer, Inc.) due to safety concerns of increased risk of blood clots compared with other estrogen and progesterone combinations used for contraception in Canada. Diane-35 is approved for the treatment of women with severe acne, unresponsive to oral antibiotic and other available treatments, with associated symptoms of androgenisation, including seborrhea and mild hirsutism. Previous communications by Health Canada (December 2002 , April 2003 , May 2005 have highlighted the increased risk of blood clots and cautioned against the use of Diane-35 as an oral contraceptive in Canada. Health Canada is aware of the decision made by France in January 2013 to suspend the sale of Diane-35 over a period of 3 months. In France, Diane-35 has been linked to 4 deaths from venous thromboembolism over the past 25 years. Continue to counsel patients on Diane-35 about the signs and symptoms of clots, especially persistent leg swelling, leg pain and tenderness, chest pain or sudden shortness of breath, or difficulty breathing. Advise patients to seek immediate medical attention for these signs and symptoms and to inform health care providers of their current medications.
Health Canada notifies the public and health care providers that it has reviewed all available data regarding risk of diabetes and the use of statins. It concluded that the risk of diabetes appears to occur in patients with preexisting risk factors, including high levels of glucose or triglycerides, obesity or high blood pressure. The product monographs of all statins (atorvastatin, lovastatin, rosuvastatin, simvastatin, pravastatin and fluvastatin) marketed in Canada have been updated to include this information. In addition, the product monographs recommend that health care providers carefully monitor the use of statins in patients at high risk for diabetes. Counsel patients to report symptoms of increased blood sugar levels, such as frequent urination, thirst or hunger, to their health care providers.
Boehringer Ingelheim Canada Ltd. and Health Canada inform the public and health care BY ALKA BHALLA, PHARMD, CGP, BCPS PRODUCT UPDATE providers of new safety information with regards to Pradaxa (dabigatran) use in patients with prosthetic heart valves. Interim results from a 12-week, open-label, randomized, phase II trial (RE-ALIGN), comparing dabigatran (dose range 150−300 mg twice daily) and warfarin in patients with recent mechanical heart valve replacement surgery within the current hospital stay and in patients who received mechanical heart valve replacement more than 3 months before, showed excess rates of thrombosis, including valve thrombosis and stroke. In addition, more bleeding events were observed in patients managed with dabigatran than with warfarin, especially in patients who were randomized soon after mechanical valve replacement. The product monograph for Pradaxa has been updated to include the contraindication of presence of prosthetic heart valve(s) requiring anticoagulation due to valvular status itself. Advise patients to discuss further with their primary care providers. Patients on Pradaxa with prosthetic heart valves should discuss options with their health care providers.
NEW PRODUCTS
Aloxi (palonosetron 0.05 mg/mL injection and 0.05 mg capsules by Eisai Limited) is a 5-HT 3receptor antagonist approved for the prevention of acute nausea and vomiting associated with moderately emetogenic cancer chemotherapy, as well as that associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin. Aloxi is used only on the day of chemotherapy. Dose adjustments are not required for geriatric patients and in those with renal or hepatic impairment. The recommended dose for the injection is a single 0.25 mg intravenous (IV) dose administered over 30 seconds approximately 30 minutes before the start of the chemotherapy. The recommended dose for the capsule is one 0.5 mg capsule administered approximately 1 hour prior to the start of chemotherapy with or without food. The terminal half-life for the injections and capsules is approximately 37 hours. Prior to initiation of Aloxi, consider reviewing the patient's medications, as caution is advised when Aloxi is used concomitantly with other medications that increase the QT interval or in patients who have or are likely to develop prolongation of the QT interval, such as those with congenital QT syndrome or electrolyte balance. Please refer to the product monograph for further details.
Esbriet (pirfenidone 267 capsules by InterMune Canada, Inc.) is an antifibrotic/ anti-inflammatory agent approved for the treatment of mild to moderate idiopathic pulmonary fibrosis in adults. The recommended dose is titrated to a daily dose of 9 capsules daily over a 14-day period, with food to reduce nausea and dizziness. Common side effects include gastrointestinal (nausea, vomiting), skin disorders (rash, photosensitivity) and dizziness. Elevated liver enzymes have been reported; aspartate aminotransferase, alanine aminotransferase and bilirubin should be measured prior to initiation of treatment and then monthly for the first 6 months and then every 3 months thereafter. Esbriet is contraindicated in patients with concomitant use of strong inhibitors of CYP1A2 (e.g., fluvoxamine, ciprofloxacin). Smoking induces CYP1A2, which may result in an increased clearance of Esbriet. Other contraindications to Esbriet include severe hepatic impairment or end-stage liver disease and severe renal impairment (CrCl <30 mL/min) or endstage renal disease requiring dialysis. Inform patients who smoke that smoking can reduce the effect of Esbriet. Advise patients to avoid or minimize exposure to direct and indirect sunlight, including through windows and from sunlamps. Instruct patients to use an effective sunblock daily and to wear clothing that protects against sun exposure. Dose adjustments may be necessary, depending on the side effects experienced. Please refer to the product monograph for further details.
NEW INDICATIONS
Afinitor (everolimus 2.5 mg, 5 mg and 10 mg tablets by Novartis Pharmaceuticals Canada, Inc.) is now indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrazole. Additionally, it is now indicated for the PRODUCT UPDATE treatment of adult patients (≥18 years of age) with renal angiomyolipoma associated with tuberous sclerosis complex who do not require immediate surgery.
NEW STRENGTHS
Pentasa (5-aminosalicylic acid by Ferring Pharmaceuticals) is now available as a 1 g extended-release tablet. The 500 mg extendedrelease tablet is also available. Other available dosage forms include the rectal suspension (1 g and 4 g/100 mL) and the suppository (1 g).
Silenor (doxepin by Paladin Labs, Inc.) is now available as 3 mg and 6 mg tablets. Doxepin is available as a generic in various strengths, such as 10 mg, 25 mg, 50 mg, 75 mg and 100 mg capsules.
NEW DOSAGE FORMS
Apprilon (doxycycline monohydrate by Galderma Canada, Inc.) is approved for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. It is available as a 40 mg modified-release capsule. Each capsule contains 2 types of beads. The immediate-release beads contain 30 mg of doxycycline and the delayed-release beads contain 10 mg of doxycycline. Doxycycline hyclate, a different salt, is available as a generic in strengths of 20 mg and 100 mg for various indications.
NEW COMBINATION PRODUCT
Stribild, an antiretroviral agent, is a combination of cobicistat 150 mg, emtricitabine 200 mg, elvitegravir 150 mg and tenofovir disoproxil fumarate 300 mg by Gilead Sciences Canada, Inc.
NEW GENERICS
Clopidogrel 300 mg tablets are now available from Apotex, Inc. This is a new alternative to Plavix.
Entacavir 0.5 mg tablets are now available from Apotex, Inc. This is a new alternative to Baraclude.
Fenofibrate E 48 mg and 145 mg are now available from Sandoz Canada. This is a new alternative to Lipid EZ.
Montelukast 4 mg and 5 mg chewable tablets are now available from Apotex, Inc. This is a new alternative to Singulair.
Pregabalin 25 mg, 50 mg, 75 mg, 150 mg and 300 mg capsules are now available from Pharmascience, Inc. This is a new alternative to Lyrica.
Sildenafil 25 mg, 50 mg and 100 mg tablets are now available from Apotex, Inc. This is a new alternative to Viagra.
PRODUCT RECALL
Novartis Pharmaceuticals Canada, Inc. has issued a voluntary type III recall of Neoral Oral Solution (cyclosporine 100 mg/ mL oral solution, lot number H5131, DIN 02150697, expiry date January 31, 2015) at the wholesaler/distributor and pharmacist levels due to a potential defect in the neck of the glass bottle. An incorrect setup of the crimping machine resulted in damage to some bottle necks. As a result, the bottle integrity cannot be guaranteed and there may be leakage in some bottles or the bottle necks could break upon opening. The defect is limited to this lot only. Novartis Pharmaceuticals Canada, Inc. advises distributors/wholesalers/pharmacists to not dispense Neoral 100 mg/mL Lot H5131 and to return the product to CLS Med-Turn International for destruction. For further information about the recall, contact Medical Information at 1-800-363-8883.
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